What is the additional mean IOP reduction of fixed combination agents with beta blockers?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Boost your readiness for the Primary Open-Angle Glaucoma Test. Utilize flashcards and multiple-choice questions complete with hints and detailed explanations to enhance your understanding.

Multiple Choice

What is the additional mean IOP reduction of fixed combination agents with beta blockers?

Explanation:
When a beta-blocker lowers IOP by reducing aqueous humor production, adding a second agent in a fixed combination provides an extra drop by hitting another mechanism of IOP reduction. Across studies, the incremental mean IOP decrease from the companion agent in fixed combinations with a beta-blocker is about 7 mmHg on average. That extra benefit comes from the second drug acting through a different pathway (for example, carbonic anhydrase inhibition or alpha agonism), so the total effect is greater than using the beta-blocker alone. The other options tend to underestimate the typical additional reduction seen with these combinations.

When a beta-blocker lowers IOP by reducing aqueous humor production, adding a second agent in a fixed combination provides an extra drop by hitting another mechanism of IOP reduction. Across studies, the incremental mean IOP decrease from the companion agent in fixed combinations with a beta-blocker is about 7 mmHg on average. That extra benefit comes from the second drug acting through a different pathway (for example, carbonic anhydrase inhibition or alpha agonism), so the total effect is greater than using the beta-blocker alone. The other options tend to underestimate the typical additional reduction seen with these combinations.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy